Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization.

Weng Z, Ertle J, Zheng S, Lauenstein T, Mueller S, Bockisch A, Gerken G, Yang D, Schlaak JF.

PLoS One. 2013 Dec 18;8(12):e82225. doi: 10.1371/journal.pone.0082225.

2.

EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.

Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T.

J Hepatol. 2011 Dec;55(6):1309-16. doi: 10.1016/j.jhep.2011.03.007.

PMID:
21703196
3.

Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET.

Sabet A, Ahmadzadehfar H, Bruhman J, Sabet A, Meyer C, Wasmuth JC, Pieper CC, Biersack HJ, Ezziddin S.

Nuklearmedizin. 2014;53(2):39-45. doi: 10.3413/Nukmed-0622-13-09.

PMID:
24777354
4.

Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.

Golfieri R, Bilbao JI, Carpanese L, Cianni R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Cappelli A, Rodriguez M, Ettorre GM, Saltarelli A, Geatti O, Ahmadzadehfar H, Haug AR, Izzo F, Giampalma E, Sangro B, Pizzi G, Notarianni E, Vit A, Wilhelm K, Jakobs TF, Lastoria S; European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators..

J Hepatol. 2013 Oct;59(4):753-61. doi: 10.1016/j.jhep.2013.05.025.

PMID:
23707371
6.

Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion.

Reiner CS, Morsbach F, Sah BR, Puippe G, Schaefer N, Pfammatter T, Alkadhi H.

J Vasc Interv Radiol. 2014 May;25(5):747-59. doi: 10.1016/j.jvir.2014.01.025.

PMID:
24630751
7.

A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.

Kokabi N, Galt JR, Xing M, Camacho JC, Barron BJ, Schuster DM, Kim HS.

J Vasc Interv Radiol. 2014 Feb;25(2):277-87. doi: 10.1016/j.jvir.2013.11.007.

PMID:
24461133
8.

Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.

Edeline J, Crouzet L, Campillo-Gimenez B, Rolland Y, Pracht M, Guillygomarc'h A, Boudjema K, Lenoir L, Adhoute X, Rohou T, Boucher E, Clément B, Blanc JF, Garin E.

Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):635-43. doi: 10.1007/s00259-015-3210-7.

PMID:
26455499
9.

Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma.

Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, Staley CA 3rd, Kim HS.

J Vasc Interv Radiol. 2010 Feb;21(2):224-30. doi: 10.1016/j.jvir.2009.10.013.

PMID:
20022765
10.

The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization.

Sukato DC, Tohme S, Chalhoub D, Han K, Zajko A, Amesur N, Orons P, Marsh JW, Geller DA, Tsung A.

J Vasc Interv Radiol. 2015 Jun;26(6):816-24.e1. doi: 10.1016/j.jvir.2015.01.038.

PMID:
25824315
12.

Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres.

Keppke AL, Salem R, Reddy D, Huang J, Jin J, Larson AC, Miller FH.

AJR Am J Roentgenol. 2007 Mar;188(3):768-75.

PMID:
17312067
13.

Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.

Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, Suh DJ.

Radiology. 2012 Feb;262(2):708-18. doi: 10.1148/radiol.11110282.

PMID:
22187634
14.

Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.

Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, Sulpice L, Boudjema K, Mesbah M, Guillygomarc'h A, Quehen E, Pracht M, Raoul JL, Clement B, Rolland Y, Boucher E.

Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1057-68. doi: 10.1007/s00259-013-2395-x.

15.

Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT.

Kucuk ON, Soydal C, Araz M, Bilgic S, Ibis E.

Clin Nucl Med. 2013 Jul;38(7):e283-9. doi: 10.1097/RLU.0b013e3182867f17.

PMID:
23531737
16.

Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients.

Saxena A, Meteling B, Kapoor J, Golani S, Danta M, Morris DL, Bester L.

Int J Surg. 2014 Dec;12(12):1403-8. doi: 10.1016/j.ijsu.2014.07.269.

17.

In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?

El Fouly A, Ertle J, El Dorry A, Shaker MK, Dechêne A, Abdella H, Mueller S, Barakat E, Lauenstein T, Bockisch A, Gerken G, Schlaak JF.

Liver Int. 2015 Feb;35(2):627-35. doi: 10.1111/liv.12637.

PMID:
25040497
18.

A retrospective analysis of selective internal radiation therapy (SIRT) with yttrium-90 microspheres in patients with unresectable hepatic malignancies.

Omed A, Lawrance JA, Murphy G, Laasch HU, Wilson G, Illidge T, Tipping J, Zivanovic M, Jeans S.

Clin Radiol. 2010 Sep;65(9):720-8. doi: 10.1016/j.crad.2010.05.001.

PMID:
20696299
19.

EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.

Liu L, Wang W, Chen H, Zhao Y, Bai W, Yin Z, He C, Jia J, Yang M, Xia J, Fan D, Han G.

Clin Cancer Res. 2014 Mar 15;20(6):1623-31. doi: 10.1158/1078-0432.CCR-13-1716.

Supplemental Content

Support Center